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PCLINICAL RESEARCH Coronary Artery Disease
The Anti-Ischemic Mechanism of Action of
Ranolazine in Stable Ischemic Heart Disease
Peter H. Stone, MD,* Bernard R. Chaitman, MD,† Karen Stocke, BS, MBA,† Junko Sano, MD,†
Arthur DeVault, PHD,‡ Gary G. Koch, PHD§
Boston, Massachusetts; St. Louis, Missouri; Palo Alto, California; and Chapel Hill, North Carolina
Objectives The purpose of this explanatory analysis was to investigate the relationship between ST-segment depression and
the rate-pressure product (RPP) during exercise to determine whether ranolazine’s mechanism of action was
related to a reduction in myocardial oxygen demand or preservation of myocardial oxygen supply.
Background In patients with stable ischemic heart disease, ranolazine increases exercise duration and reduces maximal ST-
segment depression while exerting minimal effects on heart rate and blood pressure, although its mechanism of
action during exercise has not been investigated.
Methods Patients with stable ischemic heart disease (n  191) were randomly allocated to a 4-period, double-blind, bal-
anced Latin square crossover study to receive placebo, and ranolazine 500, 1,000, and 1,500 mg twice daily
(bid) for 1 week each. Exercise treadmill tests were performed at baseline and at the end of each treatment pe-
riod. The RPP and ST-segment depression were assessed before starting exercise, at each stage of exercise, and
at maximal exercise.
Results Compared with placebo, ranolazine produced a dose-dependent reduction in ST-segment depression that be-
came more marked as exercise-induced ischemia became more pronounced, associated with clinically minor
decreases in heart rate and blood pressure. At 12-min exercise, the amount of ST-segment depression com-
pared with placebo and controlled for RPP was reduced by 22.3% on ranolazine 500 mg bid (p  0.137), by
35.4% on 1,000 mg bid (p  0.005), and by 45.8% on 1,500 mg bid (p  0.001).
Conclusions The progressive magnitude of ischemia reduction on ranolazine was proportionally more substantial than the
minor reductions in heart rate or RPP, suggesting that ranolazine’s beneficial mechanism of action is most likely
primarily due to an improvement in regional coronary blood flow in areas of myocardial ischemia. (J Am Coll
Cardiol 2010;56:934–42) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.042a
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sonventional antianginal medications reduce myocardial
schemia by significantly decreasing the determinants of
yocardial oxygen demand, such as heart rate, blood pres-
ure, or myocardial contractility at rest, during submaximal
xercise, and during maximal exercise (1). Ranolazine is a
ovel antianginal and anti-ischemic medication approved
or treatment of chronic angina. Although ranolazine has
een shown to increase exercise duration, time to onset of
rom *Brigham & Women’s Hospital, Boston, Massachusetts; †St. Louis University,
t. Louis, Missouri; ‡CV Therapeutics, Inc., Palo Alto, California; and the §Uni-
ersity of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Dr. DeVault
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he MARISA trial was provided by CV Therapeutics, Inc. Additional funding for
T-segment analyses of the exercise treadmill test data and statistical analyses was
rovided by CV Therapeutics. Dr. DeVault is an employee of CV Therapeutics/
ilead Sciences Corporation and owns Gilead stock and has options. Dr. Koch is
urrently the principal investigator for a cooperative agreement between Gilead Sciences
nd the University of North Carolina at Chapel Hill, with this cooperative agreement
eing previously in place with CV Therapeutics for at least 5 years. Dr. Koch is
dditionally the principal investigator for such cooperative agreements with over 20
harmaceutical companies and other companies involved in the development of new 2ngina, and time to 1-mm ST-segment depression (2–5)
ithout clinically substantial changes in heart rate or blood
See page 943
ressure (3–5), the effect of ranolazine on the association
etween myocardial ischemia and oxygen demand during
ubmaximal and maximal levels of exercise has not been
edicines including GlaxoSmithKline, Novartis, Sanofi-Aventis, Pfizer, and Astra-
eneca, although none of these other agreements have a specific relationship with this
tudy. The primary objectives and scope for all of the cooperative agreements pertain to
atters of statistical methodology for the design, analysis, and reporting of confirmatory
linical trials. Under the North Carolina Public Records Act, the objectives and scope of
hese cooperative agreements for which Dr. Koch is the principal investigator are
onsidered to be public information, for which requests can be made through the
niversity Counsel of the University of North Carolina at Chapel Hill, and so specific
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September 14, 2010:934–42 Ranolazine Mechanism of Actionnvestigated. Pre-clinical evidence suggests that ranolazine’s
echanism of action is in large part due to preservation of
yocardial blood flow during ischemia through its effects on
nhibition of the late inward sodium current, prevention of
yocardial cellular sodium overload and, consequently,
alcium overload, and thereby prevention of compression of
ntramyocardial nutritive blood vessels by diastolic myocardial
tiffness (6). If ranolazine’s beneficial mechanism of action is
elated to prevention of ischemia-induced reduction in myo-
ardial blood flow, then ranolazine’s anti-ischemia effects
hould become evident only once ischemia has developed
nd should become more marked, compared with placebo,
s exercise and ischemia progresses.
The purpose of this new explanatory analysis was to assess
he effects of ranolazine during submaximal and maximal
xercise on exercise-induced ischemia, measured by ST-
egment depression, and myocardial oxygen demand, mea-
ured as rate pressure product (RPP), utilizing a novel
tatistical approach to determine the timing and magnitude
f the anti-ischemic effect of ranolazine. This new analysis
heds light on the mechanism of action of ranolazine to
etermine whether ranolazine’s anti-ischemic effects were
ue to a decrease in myocardial oxygen demand or to
mproved myocardial perfusion.
ethods
tudy design. The dataset from the MARISA (Mono-
herapy Assessment of Ranolazine In Stable Angina) trial
2) was used for this analysis. The MARISA study was a
ulticenter, randomized, double-blind, balanced Latin
quare crossover trial in which patients received placebo and
ustained-release ranolazine formulation at doses of 500,
,000, and 1,500 mg twice daily (bid) for 1 week each in
andom order. Its treatment sequence groups for the order
f the 1-week periods in which the treatments were invoked
ere as follows: 500, 1,000, 1,500, placebo; 1,000, placebo,
00, 1,500; 1,500, 500, placebo, 1,000; and placebo, 1,500,
,000, 500 so that each treatment followed each of the other
reatments in exactly 1 sequence group. An exercise tread-
ill test (ETT) was performed at baseline and at the end of
ach 1-week treatment period. Although the 1,500 mg bid
ose is not approved by the Food and Drug Administration
or routine clinical use because of excessive side effects (2),
e included the 1,500 mg dose in this analysis because this
igher dose provided another efficacy data point, enhancing
ur ability to address the concept of ranolazine’s dose-
esponse relationship and because the complete data utiliz-
ng 1,500 mg bid daily were present in the dataset.
tudy population. As previously reported, the MARISA
rial (2) enrolled patients who were 21 years of age or older
ith coronary artery disease and at least a 3-month history
f stable exertional angina. After an initial single-blind
lacebo qualifying phase, ETTs were performed, and pa- bients who had exercise-limiting
ngina and ST-segment depres-
ion 1 mm between 3 and 9
in during the tests were ran-
omly assigned to the double-
lind phase of the trial. Exclu-
ion criteria included resting ST-
egment depression 1 mm in
ny lead that would preclude ac-
uracy of interpretation of ST-
egment changes, class III or IV congestive heart failure,
nstable angina, myocardial infarction, or a coronary revas-
ularization procedure in the 2 months preceding the trial.
xercise protocol. The ETTs were conducted according to
he modified Bruce protocol (i.e., progressive 3-min stages
tarting at 1.7 mph at a 0% gradient, increasing to 1.7 mph
t a 5% gradient, then 1.7 mph at a 10% gradient, and finally
.5 mph at a 12% gradient). A supine 12-lead electrocar-
iogram (ECG) was obtained before each test, and standing
CGs were monitored throughout exercise testing. Resting
CGs were classified according to the Minnesota code, and
ustomized software was used to analyze the exercise ECGs
7). Measurements of heart rate and blood pressure were
ade at 3-min intervals during each exercise test. The
TTs were conducted 4 and 12 h after dosing to correspond
ith peak and trough ranolazine plasma concentrations.
he ST-segment depression was determined in 11 leads
excluding aVR) at baseline, at the end of each stage of
xercise, and at maximal exercise.
tatistical analysis. This new explanatory analysis explic-
tly examines the stages of exercise and the associated
T-segment deviations on the different regimens of rano-
azine. Analyses must first incorporate possible covariance
tructures that could accommodate both the variability
mong the periods and increasing variability in the measures
s the study subject reaches (or does not reach) longer
urations of exercise. We used the ETT data collected at
he time of peak plasma concentrations of ranolazine. The
PP (heart rate in beats/min  systolic blood pressure in
m Hg) was calculated before exercise, at each stage of
xercise, and at maximal exercise. The ST-segment changes
rom pre-exercise assessments were expressed as the sum
cross the 11 leads.
The RPP and change in ST-segment depression com-
ared with the pre-exercise values were analyzed using a
ixed-model repeated-measures analysis of variance with
xed effects for treatment sequence, treatment, crossover
eriod, exercise stage and the interaction of treatment with
xercise stage, and a repeated-measures covariance structure
pecified for STAGE and PERIOD within SUBJECT; an
xpanded model supported equality of any carryover effects
f the treatments and thereby the omission of this factor
rom the model. The use of the mixed model accounts for
issing data with the minimal assumption that the data are
issing at random (which corresponds to the missing data
Abbreviations
and Acronyms
bid  twice daily
ECG  electrocardiogram
ETT  exercise treadmill
test
RPP  rate-pressure
producteing only dependent on the observed data) (8). Moreover,
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Ranolazine Mechanism of Action September 14, 2010:934–42his explanatory analysis is mainly to describe the variation
or the observed data (rather than to have a predictive
tructure that encompasses both the observed and missing
ata).
A relevant component of the model for this purpose is the
nteraction of treatment with exercise stage as it enables the
stimation of treatment differences separately within each of
he respective exercise stages, with the recognition that the
issing data are mainly due to some patients not reaching
he later exercise stages. As in all situations with missing
ata, more caution for interpretation is necessary where
issing data are more extensive such as the later stages of
xercise. The RPP and change in ST-segment depression at
ach exercise stage were estimated from the mixed model by
east squares means. Results throughout this paper are ex-
ressed as least square means SE. The same mixed model is
sed to summarize stage and treatment effects for heart rate
nd systolic blood pressure (8).
For all of these explanatory analyses, p values describe
trengths of relationships through the extent to which they
re small, rather than being criteria for formally testing
re-specified hypotheses. Accordingly, the results from these
nalyses do not have formal control for type I error, although
hose with p  0.001 would not seem to be due to chance,
articularly in view of the positive findings of the MARISA
rial for its primary and key secondary end points (2).
We chose this statistical approach since previously re-
orted analyses of the trial for efficacy end points used single
ummary measures, for example, maximum exercise dura-
ion, for the results from the entire crossover period for a
ose. These analyses did not specifically address the multi-
le stage measurements at 3, 6, 9, and 12 min of exercise
ithin the cross-over periods. These analyses also did not
eed to deal with any missing measurements at longer
lanned exercise times.
esults
tudy participants. These analyses include the 175 of the
91 randomized patients in the MARISA trial who com-
leted at least 3 of the 4 treatment periods.
ffects of ranolazine on RPP and ST-segment depression.
hanges in myocardial oxygen demand (RPP) as a function
f the dose of ranolazine and duration of exercise are
resented in Figure 1A. During placebo and active ranola-
ine therapy, RPP increased approximately linearly with
ncreasing duration of exercise. Changes in heart rate and
lood pressure as a function of dose of ranolazine and
uration of exercise are presented in Table 1. Ranolazine
reatment was associated with minor reductions in both
eart rate and systolic blood pressure.
At submaximal exercise compared with placebo, ranola-
ine 500 mg bid had little or no effect on RPP (Table 2).
anolazine 1,000 mg bid produced small reductions in RPPhat ranged from 3.8% at 3 min (13,693  183 vs. 14,237  b84; p 0.002) to 7.2% at 9 min of exercise (18,529 264 vs.
9,969  276; p  0.001) (Table 2). Ranolazine 1,500 mg
roduced slightly greater reductions in RPP that ranged
rom 7.5% at 3 min (13,164  185 vs. 14,237  184; p 
.001) to 10.6% at 9 min of submaximal exercise (17,859 
66 vs. 19,969  276; p  0.001) (Table 2). At maximal
xercise (12-min duration), both ranolazine 1,000 and 1,500
g produced a significant reduction in RPP compared with
lacebo (21,963  493 and 21,588  480, respectively, vs.
3,933  527; p  0.001 for each) (Fig. 1A, Table 2).
The effects of ranolazine on myocardial ischemia during
xercise, as measured by change from pre-exercise levels of
T-segment depression, are presented in Figure 1B and
able 2. As exercise progressed, during submaximal exercise
schemic ST-segment depression became more marked on
lacebo, while on ranolazine, there was progressively less
ubstantial ischemic ST-segment depression in a marked
ose-dependent manner. At maximal exercise (12 min),
anolazine 1,500 mg reduced ischemic ST-segment depres-
ion from baseline by 41.0% compared with placebo (5.09
.62 mm vs. 8.63  0.73 mm; p  0.001).
The relationship between change in ST-segment depres-
ion during the exercise protocol and RPP is presented in
igure 2. The estimated mean change in ST-segment
epression at each exercise stage is plotted against the
stimated mean RPP at the same stage. With increasing
evels of myocardial oxygen demand, ranolazine produced
lear, dose-dependent decreases in myocardial ischemia
ompared with placebo, but only after a substantial amount
f cardiac work was achieved and ischemic ST-segment
epression had occurred.
The relationship between changes in ST-segment de-
ression and the respective treatments with adjustment for
PP throughout the exercise protocol was evaluated with an
xpanded mixed model that additionally included 14 sepa-
ate and connected RPP slopes per 1,000 for RPP values
rom 10,000 to 23,000 (8). Parallelism of RPP relationships
or the 4 treatments was assessed and provided reasonable
upport. This explanatory analysis provided a comprehen-
ive description of the relationship between ST-segment
hange and RPP, and its results are presented in Table 3
nd Figures 3 and 4. During the early phase of exercise (e.g.,
he first 3 min) there was a small reduction in ST-segment
epression only on ranolazine 1,000 and 1,500 mg bid
ompared with placebo. As exercise progressed, however,
he amount of ischemic ST-segment depression decreased
n a dose-dependent manner, and the reduction was even
ore pronounced with ranolazine 1,000 and 1,500 mg bid,
ompared with placebo. At peak exercise and maximum
PP achieved, there remained a dose-dependent decrease in
he magnitude of ischemic ST-segment depression. At
2-min exercise, the amount of ST-segment depression
ompared with placebo and controlled for RPP was reduced
y 22.3% on ranolazine 500 mg bid (p  0.137), by 35.4%
n 1,000 mg bid (p  0.005), and by 45.8% on 1,500 mg
id (p  0.001). The data suggested that given the same
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September 14, 2010:934–42 Ranolazine Mechanism of Actionyocardial oxygen demand (RPP), myocardial ischemia
ay be further reduced by ranolazine in a dose-dependent
anner.
In the MARISA trial (2), the overall adverse event rate
n ranolazine 500 mg bid was 16.0%, which was similar to
hat on placebo (15.6%). At ranolazine 1,000 mg bid, the
dverse event rate was 21.7%, and on 1,500 mg bid, it was
4.2%. Most of these adverse events were minor, especially
t the 500 and 1,000 mg bid regimens. The side effect
rofile observed in the MARISA trial is similar to that
bserved in much larger placebo-controlled clinical trials of
anolazine conducted and published subsequent to the
Figure 1 Effects of Ranolazine on RPP and ST-Segment Depres
Effects (least square means  SE) of ranolazine (Ran) on rate-pressure product (RPP)
stable chronic angina. (A) Effects of exercise duration and ranolazine dose on RPP. (B
depression summed over 11 leads). *p  0.05 versus placebo. Specific p values
gles  ranolazine 500 mg; black circles  ranolazine 1,000 mg; red diamonds ARISA trial (5,9,10). piscussion
he development of more effective pharmacologic treat-
ents to reduce myocardial ischemia remains an important
ealthcare priority. Recent studies underscore that revascu-
arization strategies, especially percutaneous coronary inter-
entions, do not reduce cardiac morbidity or mortality
eyond that achieved with pharmacologic management
lone (11,12). Yet, pharmacologic therapy is often inade-
uate to prevent episodes of angina and the consequences on
motional and physical well-being (13). Ranolazine is an
mportant new anti-ischemic agent that significantly im-
During Exercise
xercise-induced ischemia during submaximal and maximal exercise in patients with
ts of exercise duration and ranolazine dose on myocardial ischemia (ST-segment
ch comparison are presented in Table 2. Yellow squares  placebo; green trian-
azine 1,500 mg. Figure by Craig Skaggs.sion
and e
) Effec
for ea
ranolroves exercise duration, time to angina, and time to
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Ranolazine Mechanism of Action September 14, 2010:934–42T-segment depression either as monotherapy (2) or in
ombination with currently available antianginal drugs (e.g.,
mlodipine, atenolol, diltiazem) (5), yet its mechanism of
ction remains unclear. The present analysis shows that
anolazine, in a dose-dependent manner, clearly decreases
yocardial ischemia during submaximal and maximal exer-
ise, after the onset of ischemic ST-segment depression.
he progressive magnitude of ischemia reduction on rano-
azine was proportionally more substantial than the minor
eductions in heart rate or RPP, suggesting that ranolazine’s
eneficial mechanism of action is most likely primarily due
o an improvement in regional coronary blood flow in areas
ffects of Ranolazine on Heart Rate and Systolic Blood Pressure atTable 1 Effects of Ranolazine on Heart Rate and Systolic Blood
Heart Rate (Beats/Min)
Exercise Duration Placebo Ran 500 mg Ran 1,000 mg Ra
Pre-exercise 83.68 0.89
(n  172)
83.82 0.88
p  0.862
(n  174)
82.14 0.88
p  0.049
(n  174)
81
p
(
3 min 96.04 0.85
(n  170)
94.88 0.84
p  0.119
(n  174)
93.62 0.84
p  0.001
(n  173)
91
p
(
6 min 105.38 0.90
(n  140)
103.94 0.89
p  0.073
(n  151)
102.01 0.89
p  0.001
(n  155)
100
p
(
9 min 117.56 1.03
(n  73)
115.87 1.01
p  0.075
(n  89)
112.98 1.00
p  0.001
(n  101)
11
p
(
12 min 135.60 2.10
(n  15)
133.62 2.41
p  0.451
(n  9)
129.66 1.97
p  0.007
(n  18)
12
p
(
ote: Least squares means estimates ( SE) and contrast t test p values for comparisons with plac
reatment, crossover period, exercise stage and the interaction of treatment with exercise stage
nstructured of stages and compound symmetry on periods) in PROC MIXED in SAS version 9.1.2
Ran  ranolazine.
ffects of Ranolazine on Rate Pressure Product and Change From Pn ST-Segment Depr ssion at Each Stage f ExerciseTable 2 Effects of Ranolazin on Rate Pressure Product and Chin ST-Segment Depression at Each Stage of Exercise
Rate Pressure Product (mm Hg/min)
Exercise Duration Placebo Ran 500 mg Ran 1,000 mg R
Pre-exercise 11,278 144
(n  172)
11,272 144
p  0.965
(n  174)
11,024 144
p  0.070
(n  172)
1
3 min 14,237 184
(n  170)
13,969 183
p  0.134
(n  174)
13,693 183
p  0.002
(n  173)
1
6 min 16,675 207
(n  140)
16,347 204
p  0.102
(n  151)
15,876 204
p  0.001
(n  155)
1
9 min 19,969 276
(n  73)
19,344 268
p  0.023
(n  89)
18,529 264
p  0.001
(n  101)
1
12 min 23,933 527
(n  15)
23,540 612
p  0.568
(n  9)
21,963 493
p  0.001
(n  18)
2
ote: Least squares means estimates ( SE) and contrast t test p values for comparisons to place
reatment, crossover period, exercise stage and the interaction of treatment with exercise stage
nstructured of stages and compound symmetry on periods) in PROC MIXED in SAS version 9.1.2 (SAS I
Ran  ranolazine.f myocardial ischemia associated with submaximal and
aximal exercise.
Conventional antianginal therapies (e.g., beta-blockers,
alcium-channel blockers, and nitrates) reduce myocardial
xygen demand by reducing hemodynamic parameters, such
s heart rate, blood pressure, cardiac contractility, and
re-load (14). Such therapies reduce the RPP at rest and
uring submaximal exercise compared with placebo. Active
herapy enables the patient to exercise for longer durations
f time as myocardial oxygen demand is reduced during
ubmaximal exercise. Exercise-induced ischemia, therefore,
s accordingly reduced throughout the exercise duration,
h Stage of Exercisessure at Each Stage of Exercise
Systolic Blood Pressure (mm Hg)
0 mg Placebo Ran 500 mg Ran 1,000 mg Ran 1,500 mg
0.89
01
6)
134.99 1.17
(n  172)
134.61 1.16
p  0.755
(n  174)
134.79 1.17
p  0.870
(n  172)
132.84 1.18
p  0.079
(n  166)
0.85
01
7)
147.69 1.24
(n  170)
146.92 1.24
p  0.551
(n  174)
145.97 1.24
p  0.181
(n  173)
143.33 1.25
p  0.001
(n  167)
0.90
01
5)
157.65 1.28
(n  140)
156.88 1.26
p  0.561
(n  151)
155.28 1.25
p  0.074
(n  155)
151.38 1.27
p  0.001
(n  145)
1.00
01
6)
168.58 1.63
(n  73)
166.02 1.56
p  0.139
(n  89)
163.30 1.53
p  0.002
(n  101)
160.47 1.54
p  0.001
(n  106)
1.92
01
0)
177.12 2.81
(n  15)
175.23 3.32
p  0.623
(n  9)
170.31 2.62
p  0.035
(n  18)
170.08 2.54
p  0.031
(n  20)
mixed-model repeated-measures analysis of variance with fixed effects for treatment sequence,
ith covariance structure specified by “REPEATED STAGE PERIOD/subjectSUBJECT UN@CS” (for
nstitute, Cary, North Carolina).
xerciseFrom Pre-Exercise
Change From Pre-Exercise in ST-Segment Depression (mm)
Sum Over 11 Leads
00 mg Placebo Ran 500 mg Ran 1,000 mg Ran 1,500 mg
 146
.000
166)
 185
.001
167)
0.84 0.10
(n  167)
0.72 0.10
p  0.236
(n  171)
0.49 0.10
p  0.001
(n  168)
0.45 0.10
p  0.001
(n  162)
 207
.001
145)
2.53 0.18
(n  143)
1.95 0.18
p  0.002
(n  151)
1.60 0.18
p  0.001
(n  158)
1.42 0.18
p  0.001
(n  144)
 266
.001
106)
5.16 0.31
(n  83)
4.15 0.30
p  0.002
(n  103)
3.59 0.29
p  0.001
(n  109)
2.99 0.30
p  0.001
(n  111)
 480
.001
20)
8.63 0.73
(n  15)
7.31 0.69
p  0.122
(n  17)
5.74 0.64
p  0.001
(n  21)
5.09 0.62
p  0.001
(n  24)
mixed-model repeated-measures analysis of variance with fixed effects for treatment sequence,
ith covariance structure specified by “REPEATED STAGE PERIOD/subjectSUBJECT UN@CS” (forEacPre
n 1,50
.02
 0.0
n  16
.66
 0.0
n  16
.06
 0.0
n  14
0.57
 0.0
n  10
7.46
 0.0
n  2
ebo from
, and wre-Eange
an 1,5
0,746
p  0
(n 
3,164
p  0
(n 
5,203
p  0
(n 
7,859
p  0
(n 
1,588
p  0
(n 
bo from
, and wnstitute, Cary, North Carolina).
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September 14, 2010:934–42 Ranolazine Mechanism of Actionncluding submaximal and maximal exercise. At maximal
xercise, however, the peak RPP reductions on placebo and
ctive therapy may be the same, even though the active
herapy enabled the patient to exercise longer to achieve that
ame RPP (15).
In contrast, pre-clinical evidence suggests that the anti-
schemia effect of ranolazine is due, at least in part, to
reservation of myocardial blood flow during the ischemic
rocess (6). As a consequence of myocardial ischemia, the
ate sodium channels remain open, leading to intracellular
Figure 2 Relationship Between Changes in ST-Segment Depres
Relationship (expressed by least square means  SE) between change from pre-e
ble chronic angina treated with ranolazine (Ran) during submaximal and maximal e
cles  ranolazine 1,000 mg; red diamonds  ranolazine 1,500 mg. Figure by Cra
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p
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6 min 2.35 0.17
(n  140)
1.7
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stage, 14 rate-pressure product (RPP) slopes per 1,000 for RPP va
“REPEATED STAGE PERIOD/subjectSUBJECT UN@CS” (for unstructure
9.1.2 (SAS Institute, Cary, North Carolina).
Ran  ranolazine.odium overload (6). The myocyte extrudes the pathologic
oncentrations of sodium through the sodium-calcium ex-
hange mechanism, leading to intracellular calcium overload,
hich leads to excessive exposure of the contractile elements to
ncreased calcium ions and consequent increased tension in the
yocyte and manifestations of diastolic relaxation failure. In
re-clinical studies, this increased diastolic myocardial stiffness
esults in prolonged extravascular compression of intramural
essels and decreased myocardial oxygen supply (16). Ranola-
ine inhibits the myocardial late inward sodium current asso-
and RPP During Exercise
in ST-segment depression and rate-pressure product (RPP) in patients with sta-
e. Yellow squares  placebo; green triangles  ranolazine 500 mg; black cir-
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Ranolazine Mechanism of Action September 14, 2010:934–42iated with ischemia (17,18), and thereby inhibits the conse-
uent calcium overload and the resultant diastolic stiffness.
hus, by inhibiting the late inward sodium current, ranolazine
ay preserve or increase diastolic myocardial oxygen delivery
uring ischemia.
The time course of the beneficial effect of ranolazine we
bserved during the exercise protocol supports this putative
echanism of action. During the early phase of exercise, in
he context of minor ischemia, there is little effect of
Figure 3 Relationship Between Changes in ST-Segment Depres
Relationship (expressed by least square means  SE) between change in ST-segm
0.05 versus placebo. Specific p values for each comparison are presented in Tabl
circles  ranolazine 1,000 mg; red diamonds  ranolazine 1,500 mg. Figure by C
Figure 4 Reduction in Ischemic ST-Segment Depression Compa
Percent magnitude of reduction in ischemic ST-segment depression compared with
in Table 3. *p  0.05 versus placebo. Specific p values for each comparison are
1,000 mg; red bars  ranolazine 1,500 mg. Figure by Craig Skaggs. Abbreviationsanolazine. Basic pre-clinical studies indicate that in
ealthy, nonischemic myocytes, where the contribution of
he late sodium current is small, ranolazine does not have a
easurable effect at therapeutic concentrations (19). As
xercise proceeds in patients with coronary disease, how-
ver, and ischemia becomes more pronounced, then rano-
azine’s anti-ischemic effects become more marked in a
ose-response manner, all in the absence of a substantial
ffect on any determinant of myocardial oxygen demand.
and Exercise Time Adjusted for RPP
epression and exercise time adjusted for rate pressure produce (RPP). *p 
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September 14, 2010:934–42 Ranolazine Mechanism of Actionlthough determinants of myocardial oxygen demand are
odestly reduced by ranolazine, it appears that the most
ikely mechanism by which this anti-ischemic effect occurs
s primarily due to preservation of myocardial blood flow
uring exercise-induced ischemia.
tudy limitations. This study is limited because there were
o direct measurements of myocardial blood flow to support
he hypothesis that ranolazine indeed increased local blood
ow to ischemic areas during exercise. Pre-clinical data
rom animal models, however, indicate that ranolazine
reserves myocardial blood flow during ischemic insults
20,21). Recent studies in humans also support the concept
hat ranolazine may be beneficial by improving coronary
lood flow by either reducing compressive effects of isch-
mic contracture or by improving endothelial function, or
oth (22). A recent study of 27 patients with stable ischemic
eart disease found that ranolazine 1,000 mg bid improves
ndothelial dysfunction compared with placebo, as assessed
sing reactive hyperemia peripheral arterial tonometry of
he index finger (23). Furthermore, Venkataraman et al.
24) observed that ranolazine, at a median dose of 1,000 mg
id in patients with stable ischemic heart disease, signifi-
antly improved myocardial perfusion in zones of myocar-
ial ischemia during treadmill exercise using technetium-
9m sestamibi single-positron emission computed tomography
maging without affecting heart rate or blood pressure at rest or
t peak exercise, in an open-label nonrandomized pilot study.
It is also possible that ranolazine reduces myocardial
xygen demand through mechanisms other than reduction
f heart rate or blood pressure. Ranolazine has no effect,
owever, on reducing myocardial contractility or ventricular
re-load (25), the other 2 determinants of myocardial
xygen demand. Ranolazine may also have exerted a beneficial
etabolic effect by partially inhibiting free fatty acid substrate
xidation during ischemia, but at therapeutic concentrations,
anolazine has little or no effect in this regard (16,26). The
tudy was not designed to capture RPP and magnitude of
T-segment deviation data in a continuous manner through-
ut the exercise protocol; values of heart rate, systolic blood
ressure, and ST-segment deviation were obtained only at the
nd of each 3-min exercise stage or at peak exercise with the
ample sizes having attrition at the later stages.
To most accurately address the hypothesis that ranolazine
educed myocardial ischemia for any given RPP value, it
ould be necessary to have continuous measurements of
oth RPP and ST-segment deviation throughout the exer-
ise protocol. The explanatory analysis for this hypothesis
rovided a comprehensive description of the relationship
etween ST-segment change and RPP through its ex-
anded mixed model, additionally including 14 separate and
onnected RPP slopes per 1,000 for RPP values from
0,000 to 23,000 (8). The results for ST-segment change
djusted for RPP appear in Table 3 and Figures 3 and 4, and
hey indicate preservation of noteworthy differences from
lacebo, particularly for the 1,000 and 1,500 mg doses at the
- and 12-min stages of exercise, although some caution isecessary for interpretation at the 12-min stage of exercise
ecause of the relatively small sample size there. Lastly, the
,500 mg bid dose of ranolazine, which was most effective in
mproving regional myocardial perfusion during ischemia, is
ot available for routine clinical use because of excessive side
ffects (2).
onclusions
anolazine over the dose range of 500 to 1,500 mg twice
aily clearly improves exercise-induced ischemic ST-
egment depression during submaximal and maximal exer-
ise without inducing a substantial change in the determi-
ants of myocardial oxygen demand. Thus, the anti-
schemic effects of ranolazine in stable ischemic heart
isease appear primarily to be due to an improvement in
egional coronary perfusion in areas of myocardial ischemia.
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